LivaNova (NASDAQ:LIVN) Shares Cross Below 50 Day Moving Average - Here's Why

Key Points

• LivaNova shares dipped below their 50‑day moving average, trading as low as $63.83 and last at $64.20 (down ~1.4%) versus a 50‑DMA of $64.71 and 200‑DMA of $61.53.
• Analyst sentiment is mixed but skewed positive: seven Buys, two Holds and one Sell produce a “Moderate Buy” consensus with a $74.78 average price target, while recent targets range from Goldman’s $66 to Needham’s $81.
• Recent results beat expectations—EPS $0.86 and revenue $360.9M (up 12.2% YoY)—and the company guided FY2026 to 4.150–4.250 EPS, though it still reports a negative net margin and a negative P/E.

LivaNova PLC (NASDAQ:LIVN - Get Free Report)'s stock price passed below its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $64.71 and traded as low as $63.83. LivaNova shares last traded at $64.20, with a volume of 394,017 shares traded.

Wall Street Analyst Weigh In

LIVN has been the subject of a number of research reports. Needham & Company LLC boosted their price target on LivaNova from $64.00 to $81.00 and gave the company a "buy" rating in a report on Wednesday, February 25th. Weiss Ratings reaffirmed a "sell (d+)" rating on shares of LivaNova in a research report on Friday, March 27th. The Goldman Sachs Group reiterated a "neutral" rating and issued a $66.00 target price on shares of LivaNova in a report on Friday, January 9th. Barclays increased their price target on LivaNova from $67.00 to $73.00 and gave the stock an "equal weight" rating in a research report on Friday, February 27th. Finally, Stifel Nicolaus set a $80.00 price target on LivaNova in a research note on Wednesday, February 25th. Seven research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $74.78.

LivaNova Trading Down 1.4%

The stock has a market capitalization of $3.51 billion, a P/E ratio of -14.39 and a beta of 0.97. The stock's 50 day moving average price is $64.71 and its 200-day moving average price is $61.53. The company has a quick ratio of 1.16, a current ratio of 1.36 and a debt-to-equity ratio of 0.29.

LivaNova (NASDAQ:LIVN - Get Free Report) last issued its quarterly earnings data on Wednesday, February 25th. The company reported $0.86 EPS for the quarter, topping analysts' consensus estimates of $0.80 by $0.06. The company had revenue of $360.92 million during the quarter, compared to the consensus estimate of $354.31 million. LivaNova had a negative net margin of 17.46% and a positive return on equity of 16.54%. LivaNova's revenue for the quarter was up 12.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.81 earnings per share. LivaNova has set its FY 2026 guidance at 4.150-4.250 EPS. As a group, equities research analysts expect that LivaNova PLC will post 3.66 earnings per share for the current year.

Institutional Investors Weigh In On LivaNova

Institutional investors have recently added to or reduced their stakes in the stock. Hantz Financial Services Inc. raised its holdings in LivaNova by 159.9% in the fourth quarter. Hantz Financial Services Inc. now owns 434 shares of the company's stock worth $27,000 after purchasing an additional 267 shares in the last quarter. State of Wyoming bought a new stake in shares of LivaNova in the 2nd quarter valued at about $31,000. EverSource Wealth Advisors LLC boosted its holdings in shares of LivaNova by 998.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 703 shares of the company's stock valued at $32,000 after buying an additional 639 shares in the last quarter. Quarry LP purchased a new position in shares of LivaNova in the 3rd quarter worth approximately $36,000. Finally, UMB Bank n.a. grew its position in shares of LivaNova by 63.0% in the 3rd quarter. UMB Bank n.a. now owns 792 shares of the company's stock worth $41,000 after buying an additional 306 shares during the last quarter. Institutional investors own 97.64% of the company's stock.

LivaNova Company Profile

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company's primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.